Pooled data from four clinical trials evaluating Bristol-Myers Squibb's (BMY -0.2%) Opdivo (nivolumab) in previously treated patients with advanced non-small cell lung cancer (NSCLC) showed that 14% of patients receiving Opdivo were alive at year 4. 19% of treated patients with PD-L1 expression of least 1% were alive at year 4, well above 11% for those with PD-L1 less than 1%.
No new safety signals were observed.
The results were presented at AACR in Atlanta.
Subscribe for full text news in your inbox